PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Seralutinib

Status:

Phase 3

Condition:

Pulmonary Hypertension ILD

Intervention Type:

Inhaled Drug

Funder Type:

Industry

Drug Details

Seralutinib is an inhaled, investigational, small-molecule kinase inhibitor designed to treat pulmonary arterial hypertension (PAH).

Study Purpose

A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of inhaled Seralutinib in treating pulmonary hypertension associated with interstitial lung disease (ILD).